From biology to clinical experience: evolution in the knowledge of neuroendocrine tumours

Main Article Content

Emilio Bajetta *
Giuseppe Procopio
Sara Pusceddu
Filippo Pietrantonio
Massimo Milione
Marco Maccauro
Elena Verzoni
Valentina Guadalupi
Marco Platania
(*) Corresponding Author:
Emilio Bajetta | emilio.bajetta@istitutotumori.mi.it

Abstract

Neuroendocrine tumours (NETs) represent a group of neoplasias characterized by significant histopathological and biological heterogeneity. Diagnosis of neuroendocrine tumours relies upon histological examination augmented by newer techniques, such as pet-dotatoc scan. Surgery represents the only curative therapeutic approach. In advanced unresectable disease, medical treatment is the best choice. Somatostatin analogues allow adequate control of the carcinoid syndrome with a low effect on tumour cell growth. Chemotherapy has a good activity only in poor prognosis patients. According to the clinical course of the disease, a multimodal approach could be evaluated in selected cases. New target therapy including multikinase inhibitors, monoclonal antibody and m-tor inhibitors is now under clinical investigation for the treatment of advanced NETs. Preliminary results demonstrated a good activity in terms of disease control rate and tumour shrinkage.

Downloads month by month

Downloads

Download data is not yet available.

Article Details